ライフサイエンスコーパス: RAR

1 RAR alpha can interact with ER-binding sites, but this o

2 RAR signaling upregulates two important genes, Tbx1 and

3 RAR-related orphan receptor-gammat (ROR-gammat) directs

4 RAR/RXR and AhR pathways cross-talk at the levels of lig

5 RAR/RXR heterodimers transduce the RA signal, and loss-o

6 RARs control multiple genes, whereas RXRs serve as partn

7 posite fetal risk was lowest with LMWH (13%; RAR: 0.3; 95% CI: 0.1 to 0.8), compared with VKA (39%),

8 terval [CI]: 1.5 to 7.5), LMWH and VKA (16%; RAR: 3.1; 95% CI: 1.2 to 7.5), or UFH and VKA (16%; RAR:

9 1; 95% CI: 1.2 to 7.5), or UFH and VKA (16%; RAR: 3.1; 95% CI: 1.5 to 7.1).

10 sly unidentified IL-23 receptor (IL-23R)(+), RAR-related orphan receptor gammat (ROR-gammat)(+)CD3(+)

11 Our findings implicate a RAR-beta/MLC-2 pathway in peritumoural stromal remodelli

12 te cell cycle and cancer cell apoptosis in a RAR-independent fashion, thereby avoiding atRA's toxicit

13 ultaneous mutation of these motifs abolishes RAR binding and concomitantly leads to loss of repressio

14 previously demonstrated that retinoic acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers

15 hat the diminished ability of RA to activate RAR following induction of differentiation stems from do

16 beta-apocarotenoids significantly activated RARs.

17 peptide in vitro, its potency in activating RAR-controlled genes in cell-based assays was much lower

18 -repressor (c-SMRT), a constitutively active RAR (VP16-RARgamma2), or by treatment with an RARgamma-s

19 novel paracrine loop controlled by adipocyte-RAR that regulates the mammary ductal tree morphogenesis

20 helium showed that when activated, adipocyte-RARs contribute to generation of secreted proliferative

21 large number of genes regulated by adipocyte-RARs.

22 The high-affinity Ajuba-RAR/RXR interaction site overlaps the region responsible

23 ine methyltransferase-5) inhibited the Ajuba/RAR interaction.

24 er effect depended on the RA receptor alpha (RAR alpha) but did not require Smad3, despite the fact t

25 s fused to the retinoic acid receptor alpha (RAR).

26 Retinoic acid receptor-alpha (RAR alpha) is a known estrogen target gene in breast can

27 tinoic acid receptor-related receptor alpha, RAR may act as a novel component to induce hepatic FGF21

28 In addition, an RAR-gamma agonist blocked heterotopic ossification in tr

29 treated mouse mesenchymal stem cells with an RAR-gamma agonist and transplanted them into nude mice.

30 Publicly available AR and RAR ChIP-seq data was used to find gene potentially regu

31 to find gene potentially regulated by AR and RAR.

32 ice induced expression of PPARbeta/delta and RAR target genes involved in regulation of lipid homeost

33 ERalpha- and RAR-binding sites appear to be coevolved on a large scal

34 nts that enhance RAR repressor function; and RAR/Zac1 function on aggrecan expression may involve Sox

35 s, a portion of T-cell clones both GATA3 and RAR-related orphan receptor C (RORC) or RORC alone, conf

36 17 cell differentiation, including Il6ra and RAR-related orphan receptor gamma (Rorc), but not of Il4

37 Using structural and biophysical methods and RAR as a model, we could dissect the molecular mechanism

38 t both delivery of ligand to the nucleus and RAR activation favor retinoic acid over dihydroretinoids

39 romyelocytic leukemia zinc finger (PLZF) and RAR-related orphan receptor gamma (RORgammat).

40 unds as the ligands of Crabp1 to rapidly and RAR-independently activate extracellular signal regulate

41 f tumor suppressor genes such as RASSF1A and RAR-beta, which are frequently silenced in human lung ca

42 e activation by recruiting co-regulators and RAR:RXR or beta-catenin, suggesting an unexpected collab

43 vivo within their heterodimers, the RXR and RAR isotypes are not functionally redundant, and it also

44 This review discusses RA and RARs and their complex roles in innate and adaptive immu

45 tinoid and retinoic acid receptors (RXRs and RARs), leading to physiological and pharmacologic effect

46 oth proximal and distal promoter regions are RAR responsive with the latter having RA response elemen

47 ism involving a retinoic acid receptor beta (RAR-beta)-dependent downregulation of actomyosin (MLC-2)

48 a conserved RARE upstream of Fgf8 that binds RAR isoforms in mouse embryos.

49 mal promoter revealed binding sites for both RAR and NFAT.

50 ature adipocytes, allows RA to activate both RARs and PPARbeta/delta, thereby enhancing lipolysis and

51 ked either negligible or no response in both RARs and SARs of control rats.

52 CRABP2 and for transcriptional activation by RAR.

53 the transcriptional up-regulation of Mct8 by RAR is likely to be important for extraembryonic endoder

54 ting that conversion can also be mediated by RAR alpha 2.

55 RA effects are mediated by RAR/RXR receptors that we show are modified by interacti

56 The degree of control by RARs or other transcription factors would in turn depend

57 lts indicate that atRA signaling mediated by RARs is required in the adult pancreas for maintaining b

58 To define the genetic network regulated by RARs in breast cancer, we identified RAR genomic targets

59 Modulation of transcription by RARs/RXRs is achieved through two activation functions,

60 miR-18a deficiency enhanced CCR6(+) RAR-related orphan receptor (ROR)gammat(+) Th17 cell dif

61 uggested that reagents blunting donor T-cell RAR signaling may possess therapeutic anti-GVHD properti

62 yoid bodies or F9 embryonal carcinoma cells, RARs occupy a large repertoire of sites with DR0, DR8, a

63 osynthesis, and requires Med25 to coordinate RAR, STAT6 and chromatin remodeler, Brg1 to remodel the

64 d proteins GATA3 and IL-4 without decreasing RAR-related orphan receptor gamma (RORgammat), IL-17, an

65 CD4(+) T cells is not a result of defective RAR-related orphan receptor gammat (RORgammat) expressio

66 pendent reporter gene and several endogenous RAR-regulated genes in a dose-dependent and gene-specifi

67 or Zac1 or pharmacologic agents that enhance RAR repressor function; and RAR/Zac1 function on aggreca

68 on-specific enhancer that contains essential RAR, T-bet, and Sox3 motifs.

69 that RARgamma is the most strongly expressed RAR in mouse growth plate and its expression characteriz

70 for E-cadherin, 25.9% for p16, and 27.5% for RAR-beta(2).

71 transactivation-based functional assays for RAR-related orphan receptor A (RORA), Herpes simplex vir

72 Our studies establish that hypomorphism for RAR in beta-cells leads to an age-dependent decrease in

73 Our results show that UTX is important for RAR-mediated transcription and provide insight into the

74 Thus, it seems that the binary model for RAR function does not apply to all in vivo scenarios.

75 dependent manner, providing a novel role for RAR alpha that is independent of its classic role.

76 These results establish a novel role for RAR as a regulator of spatial patterning of the PPE thro

77 DCA7L, CDK6, BTG1 and SAMD3) were tested for RAR and AR binding and two of them (CDCA7L and CDK6) pro

78 teract with their DNA response elements (for RARs: retinoic acid response elements or RAREs) in the r

79 le genes, whereas RXRs serve as partners for RARs and other nuclear receptors that regulate metabolis

80 udies reveal novel tissue-specific roles for RARs in controlling the competence and sensitivity of ce

81 dence that the retinoic acid receptor gamma (RAR-G) plays a major role in the regulation of the hTGP

82 ving a nuclear retinoic acid receptor-gamma (RAR-gamma) agonist.

83 /RXR-alpha and retinoic acid receptor-gamma (RAR-gamma)/RXR-beta are bound as repressing complexes to

84 ata-3(+/nlslacZ) (Gata-3-haploinsufficient), RAR-related orphan receptor alpha (RORalpha)(fl/fl)IL7R(

85 The hepatic RAR-FGF21 pathway may represent a potential drug target

86 However, whether hepatic RAR is linked to FGF21 in the control of lipid metabolis

87 IFN regulatory factor 4 and nuclear hormone RAR-related orphan receptor gammat protein levels in T c

88 Less is understood about how RAR regulates somite patterning, rostral-caudal boundary

89 ated by RARs in breast cancer, we identified RAR genomic targets using chromatin immunoprecipitation

90 During a microarray screen to identify RAR targets, we identified a subset of genes that patter

91 onal progenitors is mediated by the CRABP-II/RAR path and that the FABP5/PPARbeta/delta path can inhi

92 These findings implicate RAR alpha as an essential component of the ER complex, p

93 for growth plate function, its deficiency in RAR-mutant mice is likely to have contributed directly t

94 eated conditional mouse mutants deficient in RAR expression in cartilage.

95 of VE-cadherin was substantially reduced in RAR mutants, and this deficiency may underlie the arch a

96 elongation and are upregulated by increased RAR-mediated repression.

97 Increasing RAR signaling accelerated GVHD lethality, whereas donor

98 receptor subtype, as ATRA remarkably induced RAR-beta mRNA levels, whereas RAR-beta knockdown substan

99 In analyzing how ATRA induces RAR-dependent transcriptional upregulation of TRAIL-R1,

100 minant RAR alpha 1 isoform leaves too little RAR alpha 2 for RA to inhibit the generation of Th17 cel

101 id receptor gamma 2 (RARgamma2) is the major RAR isoform expressed throughout the caudal axial progen

102 Mean RAR differences among countries ranged from 9.4 (Singapo

103 s that atRA treatment or adenovirus-mediated RAR-alpha overexpression significantly reduced hepatic f

104 determine the role of CYP26A1 in modulating RAR activation via formation and elimination of active r

105 a histone acetyltransferase CBP to the Ngn2/RAR-complex, markedly inducing histone H3/H4-acetylation

106 tivator promotes formation of nonsymmetrical RAR homodimers with a 21 stoichiometry.

107 These findings identify Acinus-S' as a novel RAR-interacting protein that regulates the expression of

108 Consistent with this observation, RAR binding to DR-11, but not to Pal-17, was detected by

109 The differential ability of RAR-RXR bound to DR0 compared to DR2, DR5, and DR8 to me

110 by concomitantly promoting the activation of RAR and inhibiting the activation of PPARbeta/delta, SLC

111 s occurred through synergistic activation of RAR and RXR nuclear receptors.

112 thus impairs CRABP-II-mediated activation of RAR.

113 Antagonism of RAR signaling and deficiency in RARalpha (Rara(-/-)) res

114 oprecipitation assay demonstrated binding of RAR and retinoid X receptor to the RA response element.

115 The consequence of RAR alpha induction by estrogen was previously unknown.

116 monstrate that Ripply3, acting downstream of RAR signaling, is a key player in establishing boundarie

117 eadily found at the RARE control elements of RAR endogenous target genes.

118 ose a parsimonious model of the evolution of RAR function during chordate anterior-posterior patterni

119 is promoted by the estrogen-ER induction of RAR alpha.

120 Finally, pharmacologic inhibition of RAR activation during the differentiation of the murine

121 The inhibition of RAR signaling augmented donor-induced Treg generation an

122 CRABP-II thus facilitates the ligation of RAR and markedly enhances its transcriptional activity.

123 This prevailing model of RAR mechanism has been derived mostly from in vitro stud

124 cinus-S' is sufficient for the repression of RAR-regulated gene expression.

125 the first comparative studies of the role of RAR isoforms in CD8(+) T cell immunity.

126 ously unrecognized but frequent signature of RAR binding elements.

127 I-beta-mediated transcriptional silencing of RAR-beta Notably, EAD was the most effective combination

128 that regulates the expression of a subset of RAR-regulated genes through direct binding to the N-term

129 lta and is further enhanced by activation of RARs.

130 n immunoprecipitation assays, the binding of RARs to the proximal RARE1 and distal RARE2, -3, and -4

131 irect binding to the N-terminal B domains of RARs.

132 rs and their influence(s) on the function of RARs are poorly understood.

133 etinoic acid in promoting the interaction of RARs with a coactivator peptide in vitro, its potency in

134 fied that regulate the multifaceted roles of RARs in the salamander limb including regulation of skel

135 antagonized ATRA-induced transactivation of RARs.

136 ts for the repressive effect of Acinus-S' on RAR-dependent gene expression.

137 y all-trans retinoic acid via RARA and other RARs.

138 d stimulated Nrip1 expression, whereas a pan-RAR antagonist strongly reduced it.

139 The pan-RAR agonist 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetrame

140 being the RARgamma agonist CD437 and the pan-RAR agonist TTNPB.

141 PML-RAR, however, is not sufficient to induce disease in mic

142 c leukemia-retinoic acid receptor alpha (PML-RAR-alpha) oncoprotein.

143 rmalities such as oncogenes BCR-ABL1 and PML-RAR, mutations in BRCA1 and/or BRCA2 genes, and gene exp

144 ncofusion proteins, such as AML1-ETO and PML-RAR-alpha, involves the targeting of histone deacetylase

145 f APL, Hdac1 counteracts the activity of PML-RAR in (1) blocking differentiation; (2) impairing genom

146 ed to an expansion of a subpopulation of PML-RAR-expressing cells that is the major source of leukemi

147 (HDACs) by the oncogenic fusion protein PML-RAR is involved in the pathogenesis of acute promyelocyt

148 locytic leukemia-retinoic acid receptor (PML-RAR)alpha (PR), the fusion protein that initiates acute

149 -mediated proteasomal degradation of the PML-RAR fusion protein.

150 rthermore, the induced expression of the PML-RAR-alpha oncoprotein increased the expression of cell s

151 ease by promoting the destruction of the PML-RAR-alpha oncoprotein.

152 activity observed after induction of the PML-RAR-alpha oncoprotein.

153 ls such that a deficiency of the predominant RAR alpha 1 isoform leaves too little RAR alpha 2 for RA

154 ding assays demonstrated that these putative RAR antagonists compete directly with retinoic acid for

155 e assigned to 1 of 32 risk at randomization (RAR) groups created to share one-thirty-second of total

156 BP-II directly binds to the nuclear receptor RAR to form a complex through which RA is "channeled" fr

157 e identified several retinoic acid receptor (RAR) agonists that reduced secreted ApoC-III levels in h

158 n (h) ADA3 regulates retinoic acid receptor (RAR) alpha-mediated transactivation.

159 he nuclear receptors retinoic acid receptor (RAR) and peroxisome proliferator-activated receptor (PPA

160 olved the binding of retinoic acid receptor (RAR) and retinoid X receptor (RXR) to a dominant site in

161 ion was inhibited by retinoic acid receptor (RAR) antagonists or siRNAs, but augmented by several RAR

162 how here the role of retinoic acid receptor (RAR) beta and alpha signalling in proliferation and diff

163 CYP26A1 and retinoic acid receptor (RAR) beta were found to be greatly inducible by atRA in

164 Retinoic acid receptor (RAR) binds Ngn2 and is thereby recruited to motor neuron

165 l crossover onto the retinoic acid receptor (RAR) compared to all-trans-retinoic acid, with select an

166 is the ligand of the retinoic acid receptor (RAR) family of transcription factors, which interact wit

167 The retinoic acid receptor (RAR) gamma agonist CD1530 was as potent an inhibitor of

168 reviously shown that retinoic acid receptor (RAR) gamma-deficient mice have hematopoietic defects, so

169 receptors including retinoic acid receptor (RAR) have been proposed to play a protective role in pod

170 lly activated by the retinoic acid receptor (RAR) in response to its natural agonist ligand, all-tran

171 y a new role for the retinoic acid receptor (RAR) in the anterior of the embryo, where RAR regulates

172 role of each of the retinoic acid receptor (RAR) isoforms in the clonal expansion, differentiation,

173 T cells expressing a retinoic acid receptor (RAR) response element luciferase reporter responded to i

174 to be controlled by retinoic acid receptor (RAR) transcription factors, but soft matrix prevents any

175 Activation of retinoic acid receptor (RAR) with all-trans-retinoic acid (RA) ameliorates gluco

176 hh), Wingless (Wnt), retinoic acid receptor (RAR), and bone morphogenetic protein (BMP).

177 ively activating the retinoic acid receptor (RAR), recruiting the coactivator PGC-1alpha and inducing

178 a dominant-negative retinoic acid receptor (RAR)-alpha mutant (RARdn) using an inducible Cre-Lox sys

179 tic silencing of the retinoic acid receptor (RAR)-beta The histone deacetylase inhibitor entinostat i

180 BMP2 in WT MSCs in a retinoic acid receptor (RAR)-dependent manner, suggesting that Rald is involved

181 oundly inhibited RXR/retinoic acid receptor (RAR)-mediated transcriptional activation.

182 xpress low levels of retinoic acid receptor (RAR)-related orphan receptor C (RORC) transcripts, these

183 he expression of the retinoic acid receptor (RAR)-related orphan receptor gammat (RORgammat).

184 imilar levels of the retinoic acid receptor (RAR).

185 tosol to the nuclear retinoic acid receptor (RAR).

186 y, the expression of retinoic acid receptor (RAR-beta) and retinoid X receptors (RXR-beta, -gamma) wa

187 All-trans-RA (tRA) and other RA receptor (RAR) agonists dramatically (>300-fold) induced Mct8.

188 ation of hepatocytes with RA or RA receptor (RAR) agonists increased CB(1)R mRNA and protein, the mos

189 ssion by activating the nuclear RA receptor (RAR) and its cognate intracellular lipid-binding protein

190 tes transcription by binding to RA receptor (RAR) and retinoid X receptor (RXR) heterodimers.

191 ession by direct interaction of RA receptor (RAR) with a target gene, but it can also act through non

192 y deliver retinoic acid (RA) to RA receptor (RAR), a nuclear receptor activated by this hormone, in t

193 tinoic acid (RA)-activated nuclear receptors RAR and PPARbeta/delta.

194 receptors (PR) and retinoic acid receptors (RAR) regulate CK5 expression and breast CSC activity.

195 ion factors such as retinoic acid receptors (RAR), peroxisome-proliferator-activated receptors (PPAR)

196 protein 5 (FABP5), retinoic acid receptors (RAR-alpha, -beta, -gamma), and retinoid X receptors (RXR

197 RA acts through activation of RA receptors (RAR), which are members of the nuclear receptor superfam

198 The retinoic acid receptors (RARs or rars) and the thyroid hormone receptors are memb

199 Retinoic acid receptors (RARs) alpha, beta and gamma are key regulators of embryo

200 ne receptors called retinoic acid receptors (RARs) and retinoid receptors (RXRs).

201 d (9cRA), activates retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in vitro.

202 vely interacts with retinoic acid receptors (RARs) and rexinoid receptor (RXRs) subtypes in a ligand-

203 tion resulting from retinoic acid receptors (RARs) competing for limiting amounts of coactivator prot

204 Retinoic acid receptors (RARs) heterodimerize with retinoid X receptors (RXRs) an

205 e role of adipocyte retinoic acid receptors (RARs) in mammary morphogenesis.

206 t activation of the retinoic acid receptors (RARs) in mouse liver and in human liver cell lines has a

207 Retinoic acid receptors (RARs) mediate RA effects by directly regulating gene exp

208 which includes the retinoic acid receptors (RARs) responsible for mediating the effects of retinoic

209 we target specific retinoic acid receptors (RARs) to either PD duplicate (RA treatment or RARgamma a

210 interacts with the retinoic acid receptors (RARs) to modulate retinoic acid transcriptional activity

211 tion and binding of retinoic acid receptors (RARs) to the Hox1-Hox5 chromatin domains, which is follo

212 tion factors termed retinoic acid receptors (RARs), but this hormone can also activate the nuclear re

213 or of agonist-bound retinoic acid receptors (RARs).

214 iption factors, the retinoic acid receptors (RARs).

215 ly to activation of retinoic acid receptors (RARs).

216 factors, including retinoic acid receptors (RARs).

217 ated by the nuclear retinoic acid receptors (RARs).

218 binding to nuclear retinoic acid receptors (RARs).

219 a stimulation of rapidly adapting receptors (RARs) by capsaicin.

220 within cells to both its nuclear receptors (RARs) and degrading enzymes (Cyp26s).

221 ation of the nuclear receptors RA receptors (RARs) and peroxisome proliferator-activated receptor bet

222 noic acid (RA) are mediated by RA receptors (RARs) and retinoid X receptors (RXRs).

223 cription by binding to nuclear RA receptors (RARs) at RA response elements (RAREs), but it is unknown

224 RA receptors (RARs) have been thought to function through a binary rep

225 nce supports a role for RA and RA receptors (RARs) in synaptic plasticity in the brain.

226 ive toxicity caused by nuclear RA receptors (RARs) limits its clinical application in treating cancer

227 his canonical function, RA and RA receptors (RARs), either as ligand-receptor or separately, play ext

228 Recombinant RAR-RXR binds these non-canonical spacings in vitro with

229 Interleukin (IL)-6 strongly reduced RAR alpha expression levels such that a deficiency of th

230 ily warfarin and those with an LMWH regimen (RAR: 0.9; 95% CI: 0.3 to 2.4).

231 t half-site spacing allosterically regulates RAR function.

232 tionary history: recent African replacement (RAR) and archaic admixture (AA).

233 ared with LMWH (16%; ratio of averaged risk [RAR]: 3.2; 95% confidence interval [CI]: 1.5 to 7.5), LM

234 of perturbations in the NFkappaB-RORgammat (RAR-related orphan receptor gammat) axis.

235 a novel homeostatic regulator of RXR and RXR/RAR that might contribute to hepatocarcinogenesis.

236 Numbers of patients sharing the same RAR group were compared between higher and lower enrolli

237 nrolling lower-risk patients shared the same RAR group with patients from countries enrolling higher-

238 agonists or siRNAs, but augmented by several RAR agonists.

239 UTX occupies the promoters of several RAR target genes and regulates their transcriptional out

240 n and restoration of epigenetically silenced RAR-beta expression.

241 To study skeletal-specific RAR function, we created conditional mouse mutants defic

242 tion of myotome subdivisions or the specific RAR subtype that is required for somite patterning.

243 in the tissues where it acts by stimulating RAR and RXR receptors, RA signaling during development i

244 ly represses HSPs through factors other than RAR, PPAR or NFkappaB despite the presence of these fact

245 in activation of PPARbeta/delta rather than RAR.

246 We found that RAR binding throughout the genome is highly coincident w

247 The data indicate that RAR-gamma agonists are potent inhibitors of heterotopic

248 ize embryos to RA treatment, indicating that RAR availability is not limiting in the embryo.

249 We show, on a genome-wide scale, that RAR alpha and ER can co-occupy regulatory regions togeth

250 We now show that RAR alpha is required for efficient estrogen receptor-al

251 Previous studies have suggested that RAR is present in the caudal domain, but is quiescent un

252 In sum, our data reveal that RARs, and RARgamma in particular, exert previously unapp

253 The RAR alpha 1 isoform was not essential for RA-dependent e

254 The RAR interaction domains of CBP and PCAF were not require

255 The RAR-related orphan receptor gamma t (RORgammat) is a nuc

256 e transcription of Fgf21 is increased by the RAR agonist RA and by overexpression of RARalpha and RAR

257 s meiotic initiation through controlling the RAR-dependent expression of Stra8.

258 ing and topology of binding elements for the RAR-RXR heterodimer.

259 lso resulted in a comparable decrease in the RAR-mediated induction of both Sox9 and HoxA1.

260 Rarbeta2 is the RAR subtype whose expression is most upregulated in resp

261 inhibit the process through induction of the RAR repressors SIRT1 and Ajuba.

262 s cultured in the absence or presence of the RAR-specific ligand all trans retinoic acid (RA).

263 onfiguration, it has been suggested that the RAR provides a binding site for a corepressor (SMRT or N

264 evated cholesterol efflux in response to the RAR ligand ATRA.

265 es that are significantly unlikely under the RAR model and fit expectations better under a range of a

266 ion years is a statistical outlier under the RAR model; however, the large variance associated with t

267 A expression appeared to be mediated via the RAR-beta receptor subtype, as ATRA remarkably induced RA

268 l agent by increasing DRA expression via the RAR-beta/HNF-1beta-dependent pathway.

269 ses, cells that had been pretreated with the RAR-gamma agonist did not, suggesting that they had lost

270 MCF-7 cells express all three RAR isoforms, alpha, beta, and gamma, and RXRalpha.

271 nfirmed that ATRA exerts its effects through RAR-beta.

272 he inhibition of CK5+ cell expansion through RAR/PR cross talk, may explain the efficacy of retinoids

273 neuronal differentiation is mediated through RAR in the early stages and through PPARbeta/delta in th

274 g the transcriptional activity of RA through RAR, and they demonstrate that repression of this gene i

275 LBD were less conserved: Sequences of THRs, RARs and RXRs were >/=90% similar to those of the human,

276 ry tissue diverted RA from PPARbeta/delta to RAR and suppressed tumor growth.

277 5, thereby displacing RA and diverting it to RAR.

278 nding proteins-CRABP-II, which targets RA to RAR, and FABP5, which delivers it to PPARbeta/delta-furt

279 he subsequent metabolite 4-oxo-atRA, bind to RARs and potentially have biologic activity.

280 esulting in increased potency of atRA toward RAR activation.

281 and dermal fibroblasts and is regulated via RAR/RXR-mediated pathways.

282 As an explanation for the weak RAR agonist activity of dihydroretinoids in cell-based a

283 Conversely, when RAR-mediated repression is reduced by overexpressing a d

284 r (RAR) in the anterior of the embryo, where RAR regulates Fgf8 expression and formation of the pre-p

285 rkably induced RAR-beta mRNA levels, whereas RAR-beta knockdown substantially attenuated the ability

286 ese findings suggest a feedback loop whereby RARs activate expression of TNIP1, which then attenuates

287 uestion, DNA microarrays in combination with RAR isoform-specific agonists were employed to identify

288 t defective in its ability to cooperate with RAR but competent in interactions with HuR suppressed ca

289 ncogenic activities both by cooperating with RAR and by stabilizing antiproliferative HuR target tran

290 tein to nucleus and for its cooperation with RAR.

291 pathway and involves direct interaction with RAR and retinoid X receptor.

292 upstream domain in hepatocytes treated with RAR agonists or 2-AG was confirmed by chromatin immunopr

293 Based on treatments with RAR isoform-selective ligands, RARalpha is the major iso

294 Together, our studies suggest that zebrafish RAR function is context-dependent and that, during early

295 ectopic expression of hyperactive zebrafish RARs induces expression of a RA-responsive reporter tran

296 leotides to deplete the four known zebrafish RARs (raraa, rarab, rarga, and rargb).

297 ic expression of dominant negative zebrafish RARs fails to induce embryonic phenotypes that are consi

298 and that, during early patterning, zebrafish RARs function primarily as transcriptional activators an

299 Ectopic expression of wild-type zebrafish RARs does not disrupt embryonic patterning and does not

300 Here, we investigate whether zebrafish RARs function as transcriptional activators or repressor